According to the Zhitong Finance APP, WuXi AppTec-B (02126) announced its interim performance for the six months ending June 30, 2024, with the group generating revenue of 86.815 million yuan (RMB, the same below), maintaining relatively stable year-on-year; gross profit of 43.745 million yuan, also maintaining relatively stable year-on-year; and research and development expenses of 0.151 billion yuan.

The announcement stated that the stable sales performance is due to the continued commercialization of the group's targeted CD19 autologous CAR-T cell immunotherapy product, Relmacel (research code: JWCAR029). Relmacel has been approved for the treatment of adult patients with r/rLBCL and r/rFL. With the market continuing to evolve, the group expects the sales revenue of Relmacel to continue increasing. Relmacel has outstanding product characteristics that can bring breakthrough value to patients, and more indications are expected to be approved.

For the six months ending June 30, 2024, as an innovative biotech company focused on developing, producing, and commercializing cell immunotherapy products, the group has made significant progress in its business and achieved important milestones. Overall operating efficiency has improved, with stable gross margin, well-controlled sales expenses, streamlined organization, and reduced net cash outflow. The group's leading product, Relmacel, continues to make significant progress in commercialization. In addition, with excellent clinical development and operational capabilities, the China National Medical Products Administration has approved an Investigational New Drug (IND) application for Relmacel for second-line treatment of r/rLBCL patients not eligible for transplant, and the group has enrolled patients in related clinical trials. The NMPA further approved supplemental new drug applications for Relmacel for the treatment of r/rMCL patients in August 2024 and April 2023, as well as an IND application for the treatment of systemic lupus erythematosus (SLE) with Relmacel. Relmacel is the first cell therapy product approved in China for the treatment of r/rMCL patients. The group has also initiated an investigator-initiated trial (IIT) for JWATM214 to treat advanced hepatocellular carcinoma (HCC). Furthermore, the group has made significant progress in developing innovative products with global commercialization potential.